TG Therapeutics, Inc. (TGTX)

Last Price: 40.20 (2021-05-07)

Company Description

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $0.15M
Net Income (Most Recent Fiscal Year) $-279.38M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 0.04M
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 10.18
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -183803.31%
Net Margin (Trailing 12 Months) -183802.64%
Return on Equity (Trailing 12 Months) -126.58%
Return on Assets (Trailing 12 Months) -86.23%
Current Ratio (Most Recent Fiscal Quarter) 6.99
Quick Ratio (Most Recent Fiscal Quarter) 6.99
Debt to Common Equity (Most Recent Fiscal Quarter) 0.01
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $3.95
Earnings per Share (Most Recent Fiscal Quarter) $-0.71
Earnings per Share (Most Recent Fiscal Year) $-2.42
Diluted Earnings per Share (Trailing 12 Months) $-2.39
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 141.47M
Free Float 122.79M
Market Capitalization $5.69B
Average Volume (Last 20 Days) 1.50M
Beta (Past 60 Months) 2.13
Percentage Held By Insiders (Latest Annual Proxy Report) 13.20%
Percentage Held By Institutions (Latest 13F Reports) 69.88%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%